Video
The Advancing Treatment Landscape in Amyloidosis: Are You Ready?
CME/CE INFORMATION
The Advancing Treatment Landscape in Amyloidosis: Are You Ready?
Release Date: November 16, 2022
Expiration Date: November 15, 2023
Credit Offered: AMA PRA Category 1 Credit(s)™.
TARGET AUDIENCE
This educational activity is intended for members of the cardiology and oncology healthcare teams who treat patients with amyloidosis, including cardiologists, hematologists/oncologists, nurse practitioners, and PAs.
PROGRAM OVERVIEW
This webinar features expert faculty discussing compelling questions and new treatments in both AL and ATTR amyloidosis.
Learning Objectives
Upon completion of this activity, the learners should be able to:
- Evaluate emerging therapies for the management of ATTR-CM and ATTR-PN
- Evaluate emerging therapies for the management of AL
- Identify patients with amyloidosis who may qualify for clinical trials
Faculty
Daniel Lenihan, MD
Founder and Immediate Past President
International Cardio-Oncology Society
Director, Cardio-Oncology Program and Heart Failure Clinic
Cape Cardiology
Cape Girardeau, MO
Mathew S. Maurer, MD
Arnold and Arlene Goldstein Professor of Cardiology
Professor of Medicine
Columbia University Irving Medical Center
New York, NY
Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM
Professor of Medicine and Hematology
National Amyloidosis Centre, University College London
Department of Hematology, University College London Hospitals
London, England, UK
PLANNING COMMITTEE
Daniel Lenihan, MD
Founder and Immediate Past President
International Cardio-Oncology Society
Director, Cardio-Oncology Program and Heart Failure Clinic
Cape Cardiology
Cape Girardeau, MO
Mathew S. Maurer, MD
Arnold and Arlene Goldstein Professor of Cardiology
Professor of Medicine
Columbia University Irving Medical Center
New York, NY
Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM
Professor of Medicine and Hematology
National Amyloidosis Centre, University College London
Department of Hematology, University College London Hospitals
London, England, UK
Patrick Harty, PhD
Medical Director
The France Foundation
Old Lyme, CT
INSTRUCTIONS FOR PARTICIPATION AND REQUESTING CREDIT
There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CE information, completing the activity, and completing the post-test and evaluation form.
Credit Fulfillment
- If you are requesting AMA credits or a certificate of participation, your certificate will be available for download
ACCREDITED PROVIDER
This activity is jointly provided by The France Foundation and the International Cardio-Oncology Society.
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by The France Foundation and the International Cardio-Oncology Society. The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Credit Designation
The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
All other healthcare professionals completing this course will be issued a statement of participation.
DISCLOSURE POLICY
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, The France Foundation (TFF) and the International Cardio-Oncology Society (IC-OS) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial entity. TFF and IC-OS all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs.
Furthermore, TFF and IC-OS to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and IC-OS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.
| Name of Individual | Role in Activity | Name of Commercial Interest(s) | Nature of Relationship(s) | Mechanism(s) implemented to resolve conflict of interest |
|---|---|---|---|---|
| Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM | Planning Committee Member, Faculty |
|
|
|
| Daniel Lenihan, MD | Planning Committee Member, Faculty |
|
|
|
| Heather Tarbox, MPH | TFF Staff | No relevant financial disclosures | NA | N/A |
|
Mathew Maurer, MD |
Planning Committee Member, Faculty |
1. Akcea, Inc., Alnylam, Inc., Eidos, Intellia, Ionis Pharmaceuticals, Novo Nordisk, Pfizer, Inc. |
1. Research Support |
All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Chair Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning |
|
Meghan Macdonald |
TFF Staff |
No relevant financial disclosures |
NA |
NA |
|
Patrick Harty, PhD |
Planning Committee Member, TFF Content Reviewer |
No relevant financial disclosures |
NA |
NA |
|
Stephen Casselli |
IC-OS Staff |
No relevant financial disclosures |
NA |
NA |
Disclosure of Unlabeled Use:
TFF and IC-OS require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and IC-OS do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
COMMERCIAL SUPPORT ACKNOWLEDGMENT
This activity is supported by an educational grant from Janssen and Alexion.
Disclaimer
The France Foundation and the International Cardio-Oncology Society present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, the International Cardio-Oncology Society, and the commercial supporter(s) assume no liability for the information herein.
CONTACT INFORMATION
If you have questions about this CME/CE activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Tags
Webinar | Video | Oncology | CME (AMA PRA Category 1 Credit) | 1.0 - 60 mins | Cardiology | Online | Amyloidosis |
